PD-L1 IHC, NSCLC Keytruda®
Also known as: Pembrolizumab; Programmed Death Ligand 1
Use
The Dako PD-L1 22C3 pharmDx™ kit is a qualitative assay intended for use in the detection of PD-L1 in formalin-fixed, paraffin-embedded (FFPE) in non-small cell lung carcinoma (NSCLC) using the Dako Automated Link 48 platform.
Special Instructions
PD-L1 testing will be delayed if the pathology report is not received. This test number is used for tracking oncology IHC specimens to the laboratory. Bill codes will be added when testing is complete based on the processes performed in the laboratory.
Limitations
Insufficient tumor, specimens from tumors other than non-small cell lung cancer, or slides sectioned more than one month prior to test request may lead to rejection. Ensure proper specimen preservation and timely sectioning for accurate results.
Methodology
Immunoassay (IHC)
Biomarkers
LOINC Codes
- 55229-9
- 55229-9
- 83053-9
- 77202-0
- 50595-8
- 72486-4
Result Turnaround Time
4-5 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
One tissue block or five unstained, positively charged slides less than one month old
Minimum Volume
Three unstained, positively charged slides
Container
Paraffin block or unstained, positive-charged slides
Collection Instructions
Tissue should be fixed in 10% neutral-buffered formalin for no more than 72 hours. Embed in paraffin. Slides should be no more than one month old.
Storage Instructions
Refrigerate; protect from light.
Causes for Rejection
Insufficient tumor; tumor other than non-small-cell lung cancer; slides sectioned more than one month prior to test request